The outlook of companies tied to Sildenafil's history presents a challenging investment picture . While the initial boom generated substantial gains, generic competition have significantly eroded market share . Investing in related pharmaceutical companies now requires a discerning assessment of intellectual property safeguards, evolving medical tr